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Abstract           
            At the time of antiarrhythmic surgery, cryothermal energy application by a hand-held
probe  was  used   to  complement   dissections   and  resections   and  permanently  abolish  the
arrhythmogenic substrate. Over the last decade, significant engineering advances allowed
percutaneous cryoablation based on catheters, apparently not very different from standard
radiofrequency ablation catheters. Cryothermal energy has peculiar characteristics. In fact, it
allows testing in a reversible way the effects of energy application at higher temperature, before
producing a permanent lesion at –75°C. Moreover, slow formation of the lesion allows timely
discontinuation   of   the   application,   as   soon   as   inadvertent   modifications   of   normal
atrioventricular conduction are observed during ablation in the proximity of atrioventricular node
and His bundle, avoiding its permanent damage. Over the last years, percutaneous cryothermal
ablation has been widely used for a variety of cardiac arrhythmias. From the data gathered, it is
unlikely that cryoablation will replace standard ablation in unselected cases. Nevertheless, for the
above mentioned peculiarities, cryothermal ablation has proved very effective and safe for
ablation of arrhythmogenic substrates close to the normal conduction pathways, becoming the
first choice method to ablate anteroseptal and midseptal accessory pathways. It can be also the
best treatment for ablation of the slow pathway to abolish atrioventricular node reentrant
tachycardia in pediatrics or when particular anatomy of the Koch’s triangle is observed.
Cryothermal ablation of the pulmonary veins for atrial fibrillation, although longer than
radiofrequency ablation, is not associated with pulmonary vein stenosis and is expected to be less
thrombogenic; new catheter designs for cryothermal ablation of this challenging arrhythmia are
to be tested to assess their efficacy and clinical usefulness. 
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From surgical to catheter-based cryoablation
            In the 80’s, epicardial cryoablation was introduced in antiarrhythmic surgery for ablation
of accessory pathways by Klein et al1. A hand-held cryoprobe was applied at the site where
intraoperative mapping localized the arrhythmogenic substrate. The probe   was   refrigerated to
–60°C and its effectiveness was evaluated during continuous monitoring of the cardiac electrical
activity. This method, largely used in the past2,3,4 for antiarrhythmic surgery and still in use for
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the treatment of some forms of ventricular tachycardia5,6, is safe and effective. During surgery,
cryomapping allowed precise localization of the arrhythmogenic substrate by monitoring the
effect of a cryothermal energy application with higher temperature (0 to –15°C) for a limited
time (15-30s), before producing a permanent lesion at –65°C only in the most appropriate site7. 
            In the 90’s, significant engineering advances allowed the development of systems for
percutaneous cryoablation, consisting of a steerable catheter, apparently not very different from
standard ablation catheters for radiofrequency energy delivery, and a dedicated console (Figure
1). Fluid nitrous oxide is delivered under pressure to the catheter tip through a hollow injection
tube, which runs internally for the whole length of the catheter. In a small chamber inside the tip
electrode, nitrous oxide is made expand and a liquid to gas phase change takes place with heat
extraction from the electrode-to tissue interface. The gas is constantly removed through a second
coaxial lumen inside the catheter, under vacuum. The tip temperature is constantly monitored by
the console, which in turn adjust the nitrous oxide flow to obtain and maintain the preset
temperature. Two systems for cryoablation are currently available. The first is provided by
Cryocath Technologies Inc. (Montreal, Canada) and utilizes 7 or 9 F steerable catheters with 4, 6
or 8 mm long tip electrode. The ablation catheter is connected to a dedicated console, which has
two algorithms available: 1) for cryomapping with slow decrease of the temperature to – 30°C up
for 80 s; 2) for cryoablation with faster decrease of the temperature to –75°C for up to 480 s. In
any case, the target temperature can be manually preset on the console at any value between –30
and –75°C. The second system (CryoCor Inc., San Diego, California, USA) has 10 F steerable
catheters with 6.5 or 10 mm long tip electrodes. The console has a built-in closed loop pre-cooler
for the fluid nitrous oxide, whose flow at the catheter tip is adjusted during the application to
maintain a temperature of –80°C.
Figure 1. Scheme of cryoablation system. The steerable catheter and the console are
connected by: 1) a coaxial cable, used both to deliver fluid nitrous oxide to the
catheter and to remove separately the gas from the catheter; 2) electrical cable, which
is connected both to the conventional recording system for electrograms (EGMs)
analysis and storage and to the console for reading of the tip temperature. A tank of
fluid nitrous oxide is located inside the console; the gas removed from the catheter to
the console is evacuated through a scavenging hose into the vacuum line of the
electrophysiology laboratory. The system has several sensors to avoid inadvertent
leaks of nitrous oxide into the patient body and to check connections of the different
cables to the console.   
      
Lesion formation by cryothermal energy 
            Since cryothermal energy has been widely used in surgery, the types of cellular lesion
caused by tissue freezing are well known8. The mechanisms underlying lesion formation by
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cryoenergy are two-fold: 1) a direct cell injury and 2) a vascular mediated tissue injury.
               The direct cellular injury is due to ice formation, which has different distribution
according to temperature reached during cooling. By cooling to mild temperature (0 to –20°C),
ice forms only extracellularly. Consequently, extracellular environment becomes hyperosmotic
and an intracellular to extracellular water shift occurs. This causes cellular shrinkage and damage
to membrane. Cooling to these temperature may result in cellular death, if the application is
enough prolonged. Using short applications with limited temperature, the effect produced on the
cell is reversible and cellular function recovers, although minimal cellular damage may be
produced. In the clinical use, the option of producing a functionally reversible lesion is quite
attractive to test the effect of cryoablation without producing a permanent lesion. Conversely, by
cooling down to –40°C and further, intracellular water freezes and formation of intracellular ice
results in major and irreversible disruption of organelles and cell membrane with cellular death.
Intracellular ice may propagate from one cell to another via intercellular channels. 
            The second mechanism underlying lesion formation by cryothermal energy delivery is a
vascular-mediated mechanism. In fact, the initial tissue response to cooling is vasoconstriction
with decreased blood flow.  As tissue freezes, circulation ceases uniformly in the frozen tissue.
The uniformity of cell death in a lesion produced by cryothermal energy has suggested ischemic
necrosis as the main mechanism for tissue death, although it is impossible to distinguish the
tissue damage caused by this mechanism from the one produced by intracellular ice formation.
Upon re-warming, a hyperemic response is observed with increased vascular permeability and
edema formation. Other than producing increased permeability and edema, endothelial damage
results   in   platelet   aggregation   and   micro-thrombus   formation,   with   stagnation   of
microcirculation in about 30-45 min. 
            Especially in the percutaneous closed chest cryoablation, the effect produced by energy
application is the result of a temperature gradient occurring at the electrode/tissue interface and
possibly influenced by different factors, such as contact or blood flow. At the interface, the
coldest area is the one adjacent to the catheter tip, where functional effects of energy delivery are
observed earlier. Conversely, the less cooled area is the one at the periphery of the cryolesion,
whose dimensions may also vary according to the duration of freezing. Due to limited (both in
time and temperature) cooling of outer limit of the lesion, reversible tissue damage is more likely
to occur in this area. As a consequence, the effects obtained late during cryothermal energy
application are likely to revert early upon re-warming and, therefore, any expected functional
modification induced by cryoenergy should occur early (usually within the first 30 s of the
application) in order to obtain a successful and permanent ablation of a given arrhythmogenic
substrate. 
Cryothermal vs radiofrequency energy: differences and their clinical implications
            In closed chest cryoablation, the effect of cryothermal energy application greatly depends
on the minimum temperature reached, the application duration and the temperature time
constant9. The latter value indicates the course of the descent of temperature to the target
temperature and a shorter value (expressed in seconds) identifies a more effective application.
Due to intrinsic characteristics of cryothermal energy at a fixed minimum temperature, the lesion
forms more slowly than the one produced by hyperthermic injury. This has two practical
implications. The first is that the application duration for cryoablation is significantly longer than
for radiofrequency energy and a lesion produced by cryothermal energy by a 4 mm tip 7 F
cryocatheter at –75°C for 240 s has a comparable depth to the one obtained by radiofrequency
energy applied in temperature control mode at 50 W, +70°C for 60 s10. Second, the longer
estimated time required to create a permanent lesion may be clinically useful to better modulate
the lesion formation in critical areas (i.e. close to the atrioventricular node-His bundle). In these
cases, if inadvertent modifications of conduction over the normal pathways is observed during
the application, immediate discontinuation of cryothermal energy application results in return to
Indian Pacing and Electrophysiology Journal (ISSN 0972-6292), 5(1): 12-24 (2005)Roberto De Ponti, “Cryothermal Energy Ablation Of Cardiac Arrhythmias 2005:           15
State Of The Art”
baseline conduction properties, with no permanent damage to normal conduction. Recently, it
has been demonstrated in a canine model10 that cryolesions are associated with significantly less
endothelial disruption and overlying thrombus formation as compared to lesion produced by
radiofrequency energy, regardless of the preventive use of aspirin. This characteristic could be
very important, especially when multiple and prolonged energy applications are required to treat
atrial arrhythmias in the left atrium. Unlike lesions produced by a hyperthermic injury,
cryolesions show both in open chest11 and closed chest10,12 models, a well demarcated border
zone and preservation of the extracellular collagen matrix with no collagen denaturation, nor
contracture related to hyperthermic effects. These histologic observations combine with the
clinical evidence that cryothermal energy application adjacent to coronary arteries, as well as in
venous vessels (coronary sinus, middle cardiac vein and pulmonary veins)12,13,14,15, does not
results in damage nor chronic stenosis of their lumen.  
            In the already mentioned study10, it has been pointed out that lesions by radiofrequency
energy have a comparable depth of those produce by cryoablation. Nevertheless, radiofrequency
energy ablation resulted in a highly significantly greater area and a nearly significantly larger
volume when compared to cryolesions. Moreover, colder temperatures were associated with
deeper lesions and greater area and volume were associated with use of 9 F as compared to 7 F
catheters. It is not clear why cryothermal energy produces a lesion with similar depth, but smaller
area and volume, when compared to the one produced by a “similar” radiofrequency energy
application. One plausible explanation could be the “cryoadherence” effect, which is a tight
adherence of the catheter tip to the adjacent tissue caused by cooling. Due to this effect, the
lesion produced is very focal, since the “brushing” of the tip electrode, usually observed during
radiofrequency ablation, is missing. On the other hand, the advantage of this effect is two-fold.
First, below the critical temperature of –20°C it allows good tip electrode to tissue contact,
which persists throughout the whole application and it is not dependent on the torsion/deflection
manoeuvres applied to the catheter. It is well known that a fixed and stable contact during the
whole application is essential, especially for ablation in proximity of critical areas, such as
atrioventricular node and His bundle. Second, the cryoadherence effect allows safe continuation
of the application, even when sudden changes in heart rhythm that usually displace the ablation
catheter (such as tachycardia termination or pacing) occur. Moreover, cryoadherence does not
compromise safety, since, upon discontinuation of cryothermal energy delivery, the defrost phase
is very fast (within 3 s) and the catheter can be immediately disengaged from the ablation
position. 
          Finally, another peculiarity of cryothermal energy is the complete absence of patient
symptoms in almost every case, in spite long-lasting applications. In our experience, we have
evaluated patient perceptions during cryothermal energy application in a series of non-sedated
cases. In almost all cases, the absolute absence of perception was demonstrated by the fact that
the patient was unable to tell when the application was started and discontinued. Only in some
cases, when multiple and prolonged applications are delivered in the left heart, a light sense of
cold or headache is perceived as minor discomfort. Although the full explanation of the absence
of symptoms is not completely clear, this characteristic can be particularly useful in young as
well as in paediatric patients.
Clinical use in ablation of cardiac arrhythmias
               Over the last five yeas, the world-wide experience in catheter ablation of cardiac
arrhythmias by using cryothermal energy has increased unabated. Based on this experience,
cryoablation should not be viewed as a replacement for radiofrequency energy, which will
continue to be the method of choice in many clinical situations. Nevertheless, ablation by
cryothermal energy should be rather considered as a useful addition to the electrophysiologist’s
armamentarium.  In  fact,   different   types  of  arrhythmias   are  now   successfully  treated  by
cryoablation and in some cases, especially in proximity to normal conduction   pathways,
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treatment by this energy source is considered the first choice therapy for its safety and efficacy.
The following is a brief analysis of the experience in cryoablation for each of the considered
arrhythmias. 
Atrioventricular nodal reentrant tachycardia. So far, slow pathway ablation for atrioventricular
nodal reentrant tachycardia by cryothermal energy represents the numerically larger experience
in the clinical application of this new technology. Unlike radiofrequency energy, accelerated
junctional   rhythm   is   not   observed   during   cryothermal   energy   application   on   the   slow
atrioventricular node pathway. Therefore, the only marker of effective ablation is suppression of
tachycardia  inducibility  during  initial   cooling  (Figure  2A-B).  Accordingly,  baseline   non
inducibility of the arrhythmia may be a limitation to the application of this technique. From the
early report16, several papers have contributed to accumulating experience in slow pathway
ablation, with a satisfactory success rate and a recurrence rate varying from 6 to 9.7%
17,18,19,20,21,22. In the “Frosty” trial19, a multicentric prospective trial performed in the United
States, 103 patients with atrioventricular nodal reentrant tachycardia were enrolled. On an
intention-to-treat   basis,   the   acute   procedural   success   was   91%   with   no   device-related
complications and a recurrence rate of 6% in a 6 month follow-up. Cryomapping proved useful
to predict the site of successful ablation. Nine patients had inadvertent modifications of the
conduction over normal atrioventricular conduction pathways, including first to third degree
atrioventricular block and right bundle branch block. These all resolved completely, usually
within a minute or less and had no sequelae. A database gathering the worldwide experience and
based on a combination of registry and prospective trial data reports no case of permanent
atrioventricular block following cryothermal ablation of the slow pathway in more than 300
patients with atrioventricular nodal reentrant tachycardia20. Temporary first degree or higher
atrioventricular block, observed in 15 cases (4.3%) during cryomapping at –30°C or during
cryoablation at –75°C, was always reversible. Recently, the results of the first two prospective
randomized trials on transvenous cryoablation versus radiofrequency ablation of the slow
pathway for treatment of atrioventricolar nodal reentrant tachycardia have been published21,22. In
these studies, cryoablation proved as effective and safe for the cure of atrioventricular nodal
reentrant tachycardia as radiofrequency ablation. The higher recurrence rate that may be
observed in the cryoablation group21 suggests that, unlike radiofrequency ablation, prolonged
energy applications and postablation waiting time are necessary when cryothermal ablation is
used to minimize recurrence in the follow-up. In our own experience, we treat atrioventricular
nodal reentrant tachycardia by slow pathway cryoablation in patients with particular anatomic
characteristics, refractory to standard radiofrequency energy ablation or in pediatrics. Especially
in cases with difficult anatomy, such as a small or distorted Koch’s triangle, the characteristics of
cryothermal energy allow test of the ablation effect in particularly risky sites without producing
irreversible damage to atrioventricular conduction, if the application is timely interrupted. In
some complex cases, we found it necessary to resort to longer cryothermal energy applications
(up to 480 s) and to prolong postablation observation up to 60 min. In a patient with
atrioventricular nodal reentrant tachycardia, who underwent multiple unsuccessful ablation of the
slow pathway, we decided to target the fast pathway by cryothermal energy23. In this particular
case, selective and safe ablation of the fast pathway at the apex of the Koch’s triangle was
accomplished and this resulted in permanent cure of the arrhythmia.  
            According to the presented data, cryothermal energy is a valuable and useful alternative
to radiofrequency energy to treat patients with atrioventricular nodal reentrant tachycardia.
Absence of permanent inadvertent damage of atrioventricular conduction makes this new
technology particularly useful in cases with difficult anatomy, unsuccessful prior standard
ablation procedure, in pediatrics and in all cases, in whom even the lower risk of atrioventricular
block still possible with radiofrequency energy, is considered unacceptable. 
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Figure 2A-B.  Example of suppression of inducibility of atrioventricular nodal
reentrant tachycardia during cooling of the slow pathway. Form top to bottom, lead I,
II, III, V1, V6, bipolar recordings from the coronary sinus catheter (from distal to
proximal; CS4 is used for stimulation and not visualized) and from the distal (HBEd)
and proximal (HBEp) electrode pairs of the the His bundle catheter are displayed. In
panel A, programmed atrial stimulation (p=400, 260/240) from the coronary sinus
reproducibly induces typical sustained atrioventricular nodal reentrant tachycardia. In
panel B, also bipolar recordings from the distal (ABLd) and the proximal (ABLp)
electrode pairs of the cryoablation  catheter  are  displayed. Now, during cooling  at
–30°C on the slow pathway, S3 beat is blocked even at a longer coupling interval
(S3= 290 ms) and tachycardia is no longer inducible. Artefacts in the ABLd are due
to ice formation on the tip electrode.  
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Accessory pathways.  In  Table 1,  published data on cryothermal ablation of anteroseptal
(parahissian) and midseptal accessory pathways are reported17,19,24-29. As shown, this technique
in anterospetal and midseptal areas, both at high risk of complete permanent atrioventricular
block when standard radiofrequency energy in performed, is highly safe and successful. In the
larger series, success rate is above 90%. Although transient modifications of the normal
atrioventricular   nodal   conduction   pathways   are   observed   during   cooling,   no   permanent
modifications is observed with the only exception of right bundle branch block in 2 cases in a
single centre. In fact, immediate discontinuation of cryothermal energy application at any
temperature upon observation of modification of conduction over normal pathways results in
return to baseline condition, soon after discontinuation. Resumption of accessory pathway
conduction with palpitation recurrences may occur in the follow up to 20%, but, especially in
young healthy individual, a recurrence is by far more acceptable than permanent complete
atrioventricular block requiring pacing, which was invariably the case in many series of
radiofrequency ablation of these pathways. In our experience, we have treated 18 patients with
anteroseptal or midseptal accessory pathways, so far, age ranging 11-51 years. No patient was
excluded from the study for proximity of the accessory pathway to the normal conduction
pathways (Figure 3). Successful ablation was obtained in all, but 1 pediatric and asymptomatic
patient, in whom conduction properties over the accessory pathway indicated ablation, which
was eventually postponed. Cryoadherence effect proved very useful in every case, but especially
when energy delivery was performed during orthodromic atrioventricular tachycardia, to better
visualize the His bundle electrogram and to monitor conduction over normal pathways. No
complication or palpitation recurrences were observed during a 17±10 month follow-up. In
approaching   anteroseptal   and   midseptal   accessory   pathways,   instead   of   performing
“cryomapping” at –30°C in the selected site, we found it useful to test cryothermal energy
applications with a step-by-step method to decrease temperature. In fact, in the most suitable site
with the best contact (sometimes, a superior vena cava approach via a subclavian or a brachial
vein is useful to stabilize contact), test applications are applied for 30 s, initially with a
temperature of –30°C. If this test application is successful with no modification of normal
conduction, then transition to ablation at –75°C up to 480 s is made. If the test application is
unsuccessful,   after   re-warming,   further   30s   applications   are   tested,   decreasing  for   each
application the temperature by 10°C every step, up to the last application at –70°C. This is
because we observed that the amount of cryothermal energy required for permanent ablation is
quite individual (ranging from an application of –40°C for 40s to an application of –75°C for
480 s) and limiting test applications to only –30°C may limit the applicability of cryoablation in
these patients. On the other hand, the use of cryothermal energy at temperatures lower than –30°
C should be considered safer than radiofrequency energy in these critical sites. 
               Cryoablation can be also successfully and safely used to ablate selected cases of
epicardial left-sided accessory pathways within the coronary sinus, well beyond the middle
cardiac vein, once attempts by using both transseptal and transaortic approach have failed20,30.
Similarly, safe and successful cryothermal energy ablation of permanent junctional reciprocating
tachycardia has been reported in children, in the midseptal region, at the coronary sinus os or in
the middle cardiac vein31. 
            The experience of cryoablation in unselected accessory pathways is more limited and less
satisfactory20. Of 51 accessory pathways with various locations, only 69% were successfully
ablated and this value is considerably lower than the one reported for radiofrequency ablation.
There are many possible explanations for this including the learning curve and the smaller size of
the lesion produced by cryoablation10. In any case, all the peculiarities of cryothermal energy,
which are optimal for septal ablation, are less important or even useless for ablation of accessory
pathways located elsewhere. 
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Table 1. Review of cryoablation of anteroseptal or midseptal accessory pathways
Abbreviations:   No.pts:   number  of   patients;   AntSept:   number   of  patients   with
anteroseptal  accessory  pathways;  MidSept:   number   of   patients   with   midseptal
accessory pathways; RBBB: right bundle branch block; n.r.: not reported
Focal   atrial   tachycardia   and   isthmus-dependent   atrial   flutter.  Occasionally,   successful
cryoablation of focal atrial tachycardia has been reported and its safety has been confirmed also
for ablation of atrial foci located close to the atrioventricular node32. 
            Several papers have reported cryoablation of the cavotricuspid isthmus for typical atrial
flutter   with   an   acute   and   long-term   success   comparable   to   the   one   of   radiofrequency
ablation33,34,35,36. The use of larger catheter and longer electrode for ablation in this area is
associated  with  a lower  number  of applications   and  a shorter  procedural  time.   As  for
radiofrequency ablation, a case of transient ST segment elevation in the inferior leads was
observed during cryo application at the septal isthmus, with wall irregularities in the right
coronary artery without significant stenosis35. The major advantage of using cryothermal energy
to produce bidirectional conduction block of the cavo-tricuspid isthmus is the absence of pain
perception related to energy application. In a prospective randomized trial in which a visual
analogue scale to evaluate pain was used, pain perception was by far lower if not existent in the
cryothermal as compared to radiofrequency energy group34.
Pulmonary vein ablation for atrial fibrillation. When radiofrequency energy is applied at the os
of the pulmonary veins to prevent atrial fibrillation recurrences, a heat-induced contraction of the
pulmonary vein wall can be observed early or during the follow-up, which results in a variable
degree of lumen reduction and a wide spectrum of clinical presentations37. This reaction is
typical of hyperthermic injury and results from a combination of edema, endothelial disruption
and collagen denaturation and shrinkage38. The occurrence and the degree of stenosis correlate
with the amount of energy delivered39 and lesion extension40. As mentioned above, cryothermal
energy ablation causes less or minimal endothelial disruption, maintenance of extracellular
collagen matrix and no collagen contracture related to thermal effects. Moreover, lower
incidence of thrombus formation is reported with cryoenergy as compared to radiofrequency
energy ablation. For these characteristics, cryothermal energy ablation can be considered an ideal
and safer energy source also for pulmonary vein ablation and the incidence of both pulmonary
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veins stenosis and thromboembolic events is expected to be dramatically reduced by using
cryoablation. On the other hand, the presence of high blood flow in the pulmonary vein may
represent a considerable heat load, which may limit the size and depth of the lesion produced by
cryothermal energy at the os of the pulmonary vein. Moreover, the longer time required to
produce a permanent lesion may relevantly reflect on procedure duration, limiting the clinical
use of this theoretically optimal energy source. Initial experiences of electrophysiologically-
guided segmental ostial ablation of the pulmonary vein by using cryothermal energy application
with 10 or 7 F catheters20,41 have been reported. These experiences show that pulmonary vein
isolation is feasible with a comparable number of applications and clinical outcome with regard
to radiofrequency ablation; longer procedural times, observed for both the 10 F and the 7 F
catheter,   correlate  with  longer  application  times  required  when cryothermal energy  is  used.
Figure 3.  Example of disappearance of ventricular preexcitation in a case of
parahissian accessory pathway. Surface ECG and bipolar recordings from the distal
(ABLd) and proximal (ABLp) electrode pairs of the cryoablation catheter are
displayed. The relative position of His bundle and the accessory pathway has been
identified   during   accurate   mapping,   also   during   orthodromic   atrioventricular
reentrant tachycardia. Accessory pathway turned out to be located at the same site
where a high amplitude His bundle potential was recorded. In this figure, the tip
electrode temperature is –23°C and minor artefacts in ABLd suggest that ice is
forming on the tip electrode. In the first sinus beat, ventricular preexcitation is still
present with optimal A-V and V-delta interval recorded at this site. In the second
beat, conduction over the accessory pathway is interrupted with disappearance of
ventricular  preexcitation; now a high amplitude His bundle potential is well evident
in the distal electrode pair of the ablation catheter. Permanent ablation of this
parahissian pathway could be accomplished by limited cryothermal energy delivery
in this site with no modification of conduction over the normal atrioventricular
conduction pathway.
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Importantly, the early cryoablation experience has not evidenced, so far, development of
pulmonary veins stenosis following ablation. Technologic evolution is now aimed to develop
new catheter designs for circumferential ostial ablation of the pulmonary veins, with the option
of deploying in the pulmonary veins an inflatable balloon to reduce the heat load related to blood
flow20. These devices are to be tested in a large patient cohort to assess whether these
technological improvements will lead to optimization  of the use of cryothermal energy,
maximizing the advantages of this new technology and limiting the drawbacks encountered in its
clinical use.
 
Ventricular   arrhythmias.  Although   clinical   data   on   cryothermal   ablation   of   ventricular
arrhythmias   are   missing,   preliminary   experimental   evidence   shows   that   percutaneous
cryoablation in several sites of normal ventricular myocardium is feasible with lesion deeper in
the left than in the right ventricle, probably due to better contact in the former than in the latter42.
In the same study, cryothermal energy has been also tested to ablate sustained ventricular
tachycardias in a post-infarction sheep model. A limited number of applications was effective in
suppressing the inducibility of ventricular arrhythmias, producing a transmural lesion in the
majority of the cases with no acute complication. 
              Interestingly, cryothermal energy could be used to target ventricular tachycardias of
epicardial origin, once the epicardial space has been reached by the non surgical transpericardial
approach, originally described by Sosa43. As compared to radiofrequency energy, cryothermal
energy seems to be safer in the epicardium, due to less probable damage to epicardial coronary
arteries. The reduced heat load in the pericardial space related to the absence of blood flow could
be to the advantage of cryoablation in these cases, with the possibility to produce larger
transmural lesions.  
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